Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) Spikes On Migraine Data

Zosano Pharma Corp (NASDAQ:ZSAN) Spikes On Migraine Data

Zosano Pharma Corp (NASDAQ:ZSAN) traded higher after announcing the publication of positive pivotal data for its proprietary Adhesive Dermally-Applied Microarray technology. The stock was up by 5.6% in Thursday’s trading session, to end the day at $1.13 a share.

ZSAN Stock Performance

Shares of Zosano Pharma Corp (NASDAQ:ZSAN) are currently trading in a downtrend, after dropping from $3.50 a share in February. While the stock is slightly up for the year, it has underperformed the overall industry. Data compiled by Zacks Investment Research indicates that the stock is rated as a ‘buy,’ by one analyst firm and as a ‘hold’ by another.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its ADAM technology. The investigational technology platform is designed to offer rapid drug absorption into the bloodstream resulting in improved pharmacokinetic profile compared to other dosage forms.

A publication by Cephalalgia contains positive results from Zosano Pharma Corp (NASDAQ:ZSAN)’s Zotrip Pivotal study. The multicenter, double-blind randomized trial analyzed the safety and efficacy of ADAM Zolmitriptan for the treatment of acute migraine.

“We are pleased to have the results of ZOTRIP, our pivotal study, published in Cephalalgia. The recognition of the results from ZOTRIP in such a well-known journal will continue to raise awareness of M207, and its ability to address an unmet need for patients struggling to find rapid and durable pain relief for migraine episodes,” said CEO John P. Walker.

Board Appointment

In addition to the publication, Zosano Pharma Corp (NASDAQ:ZSAN) has confirmed the appointment of Mr. Kenneth R. Greathouse to the board of directors. His experience in the field of neurology will be a key asset in bringing M207 to market.

He joins the company with over 40 years of experience in sales marketing and business development. Greathouse is also a co-founder of various pharmaceutical companies, including Manchester Pharmaceuticals.

“I look forward to working with the management team and Board as our lead program progresses towards an NDA filing and, if approved, towards commercialization,” said Mr. Greathouse.

Zosano Patent Application

Separately, Zosano Pharma Corp (NASDAQ:ZSAN) says it is in active discussions with the U.S Patent and Trademark Office (USPTO), regarding a patent application covering M207. The patent application details a method of rapidly achieving therapeutic concentrations of triptans for the treatment of migraines. If issued, the patent would extend coverage of the current patent from 2027 to 2037.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) Implodes After FDA Rejection

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares fell 59.8% after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia. The agency raised a number of issues that the company needs to address pending any future consideration.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)

FDA Recommendation

One of the recommendations requires AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) to collect additional data on at least 50 patients, assessing the safety of DSUVIA at the maximum amount described in the labeling. The company will also have to ensure proper administration of the tablet with the single dose applicator.

The regulator is also demanding changes to the “Directions for Use” instructions that come with the drug, to address issues of tablets that may need to be disposed of.

The FDA decision rattled investors as most of them were expecting the painkiller to achieve regulatory approval. Analysts were optimistic about the drug gaining regulatory approval on its limited abuse potential. The stock consequently suffered its biggest one-day sell-off since it went public in 2011.

AcelRX Defense

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has sought to quash investor concern and prevent a further slide in the stock price by insisting that the recommendations by the FDA are manageable. In a statement, the company says it will request a meeting with the FDA to discuss topics in the Complete Response Letter.

“We believe the recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA. We remain focused on the NDA resubmission and our mission to provide physicians and patients with precise and efficient non-invasive pain management options for moderate-to-severe acute pain within medically supervised settings,” said CEO Vincent J. Angotti.

The Chef Executive Officer says they have a sufficient cash runway of $67.9 million to complete the Dsuvia marketing application resubmission. The company also plans to make a marketing submission application for its other drug, Zalviso.

Opioid Epidemic

The FDA decision comes at a time when the United States is grappling with a major opioid epidemic. The agency has become cautious in recent years in issuing new approvals on heavy-duty painkillers after more than 33,000 deaths were reported in 2015.

Last month the regulator rejected another opioid painkiller from Intellipharmaceutics as it requested additional data to prove the drug’s ability to prevent abuse.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) To Make Key Presentations

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares gained 10.1% after the company said it will present updated clinical data on the study of ImmunoPulse IL-12, its lead oncology program. The biotechnology company will make the presentation at the upcoming 9th World Congress of Melanoma.

OncoSec Medical Inc. (NASDAQ:ONCS)

ImmunoPulse IL-12 Presentations

In addition, OncoSec Medical Inc. (NASDAQ:ONCS) is to present updated clinical data from its Phase 2 Investigator Sponsored trial in patients with unresectable metastatic melanoma. The presentation will occur at the upcoming Society for Immunotherapy of Cancer (“SITC”) 32nd Annual Meeting to be held on November 8-12, 2017,

ImmunoPulse IL-12 is a nonviral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body. It is currently in Phase 2 clinical monotherapy trial, for the treatment of stage three and four melanoma.

A presentation by Dr. Alain Algazi will contrast the candidate drug to its combination with pembrolizumab. The presentation will also include clinical and biomarker data from a recently completed Phase 3 monotherapy trial.

“These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration-directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018,” said CEO Punit Dhillon.

 ONCS Stock Performance

Investor confidence on OncoSec Medical Inc. (NASDAQ:ONCS) is slowly building following a string of positive news on the development of the company’s lead oncology program. The stock has bounced back from multi-year lows of below $1 a share and bullish momentum continues to grow in strength.

However, the stock is still down by more than 5% for the year after coming under pressure after rising to $1.50 share. OncoSec Medical Incorporated faces immediate resistance at $1.25 a close above which could see the stock making a push for the $1.50 mark.

OncoSec Medical Inc. (NASDAQ:ONCS) has elicited significant investor interest in the recent past as most of them take note of its robust and differentiated approach in developing cancer treatments. The company is currently merging over two decades of research and development processes to accelerate the development of its lead candidate product.

The company’s flagship product, ImmunoPulse IL-12 has already shown to deliver equal gene transmission rates while maintaining a high safety profile. OncoSec Medical Inc. (NASDAQ:ONCS) is advancing the treatment into Phase 2 trials with projected milestone for treatment approval set for 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

RXi Pharmaceuticals Corp (NASDAQ:RXII)

RXi Pharmaceuticals Corp (NASDAQ:RXII) To Make Presentation

RXi Pharmaceuticals Corp (NASDAQ:RXII)

RXi Pharmaceuticals Corp (NASDAQ:RXII) has announced that its research vice president, Karen Bulock, will make a presentation at this year’s Annual BIO Investor Forum – taking place in San Francisco, California. At the forum, Bulock will talk about the RNAi platform which is self-delivering as well as demonstrate how it can be applied in the treatment of cancer using cell-based immunotherapies.

The expected attendees of the investor conference include the industry executives of various biotech and pharmaceutical companies, research analyst, public investors, and private equity investors. The event will also be webcast.

RXi Pharmaceuticals Corp (NASDAQ:RXII)

September presentations

Last month RXi Pharmaceuticals Corp (NASDAQ:RXII) made a series of presentations at various events. This included a presentation made by the company’s intellectual property and business development director, James Cardia, at the 10th Annual International Partnering Conference which took place in Boston, Massachusetts.

At the event Cardia gave a corporate overview which included the RNA therapeutic platform which is self-delivering. Cardia also talked about the company’s ongoing clinical and research programs especially in the areas of ophthalmology, dermatology and immunotherapy. The event had drawn leaders from various sectors including pharmaceutical, finance and biotech.

Another presentation that was made last month was by the chief development officer of RXi Pharmaceuticals Corp (NASDAQ:RXII), Gerrit Dispersyn. This was at the Ladenburg Thalmann Healthcare Conference which took place in New York City. Dispersyn’s presentation revolved around RNAi which is a self-delivering platform and applicable in various therapeutic areas. His presentation also touched on various RXi programs including ophthalmology, dermatology and immune-oncology.

RXi Executive departure

Last month also saw the RXi’s chief business officer, Alexey Eliseev, leave the company. Eliseev had joined RXi at the beginning of the year after RXi acquired Mirimmune, a privately-held firm which develops therapeutics used in the treatment of cancer.

“The Company would like to thank Dr. Eliseev for his support in integrating MirImmune into our Company’s day-to-day activities, and for providing RXi exposure to some of the key players in this new and exciting space,” RXi Pharmaceuticals Corp (NASDAQ:RXII)’s chief executive officer and president, Dr. Geert Cauwenbergh, said after the departure of Eliseev.

While at RXi the group that was led by Cardia was involved in discovering and optimizing rxRNAs which are self-delivering. Cardia’s group was also responsible for the characterization and development of RXI-109, an anti-fibrotic agent which is currently being tested as a therapy for retinal and dermal scarring.

Following Eliseev’s exit, Cardia took over the business development and partnering responsibilities. Eliseev obtained a chemistry Ph.D from Boston College and received his postdoctoral training at Harvard University.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RXII Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) Skyrockets 22%

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Shares of Akari Therapeutics PLC (ADR)(NASDAQ:AKTX) skyrocketed over 22%, after the biopharmaceutical company announced further clinical progress in its ongoing Phase 2 Clinical trial of Coversin. The company is investigating the drug candidate for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Patient Enrollment

Three additional patients have been enrolled in the program, bringing the total to eight, in the open-label single-arm clinical trial. The new patients were enrolled pursuant to an amended protocol based on a revised dosing regimen. Only one patient has withdrawn from the COBALT trial so far.

The primary endpoint in the trial is the reduction of serum to less than or equal to 1.8 times the upper limit of normal for investigators reference laboratory. Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) will provide an update in all PNH patients enrolled at the America Society of Hematology Annual Meeting next month.

AKTX Stock Rating

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) is currently rated as a ‘sell’ by one investment firm according to data compiled by Zack Investment Research. The sell rating does not come as a surprise, and the stock has underperformed the overall industry this year.

Akari Therapeutics PLC (ADR)(NASDAQ:AKTX)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has shed more than 50% in market value since May after rising to $20 a share. However, the stock is flat for 2017 as it continues to trade at levels last seen in January. The stock received a boost earlier after the biopharmaceutical company said it will move forward with the Phase 3 development of Coversin on the treatment of Paroxysmal Nocturnal Hemoglobinuria.

“Following our recent FDA meeting, we are working to initiate a Phase III clinical trial of Coversin in PNH in Q1 2018,” said Dr. David Horn Solomon, Chief Executive Officer of Akari Therapeutics. “We will continue to work closely with the FDA, benefitting from our Fast Track status in the U.S., and with the EMA towards submission of a BLA and MAA, respectively, for Coversin in PNH.

PNH is a rare life-threatening disease of the blood characterized by destruction of red blood cells, blood clots, and impaired bone marrow function. The condition affects 1 to 1.5 person per million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AKTX Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cempra Inc. (NASDAQ:CEMP)

Cempra Inc. (NASDAQ:CEMP) Acquisition Target Reports Trial Results

Cempra Inc. (NASDAQ:CEMP)

Shares of Cempra Inc. (NASDAQ:CEMP) gained 1.59% after the company’s proposed acquisition, Melinta Therapeutics, announced the successful completion of a Phase 1 clinical study of a novel treatment for acne vulgaris. Preliminary results indicate that candidate drug, radezolid, was well tolerated with minimal systematic absorption.

Cempra Inc. (NASDAQ:CEMP),

Cempra-Melinta Merger

The positive clinical trial results continue to strengthen investor confidence on Cempra Inc. (NASDAQ:CEMP), pending completion of a merger of the two companies. Melinta and Cempra are close to merging after the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Both companies expect the merger to be completed in the fourth quarter, subject to satisfaction of closing conditions.

A push to acquire the privately held commercial-stage company is yet to have a significant impact on Cempra sentiments on Wall Street. The stock is still trading in a downtrend after struggling to rise above $4.70. CEMP is unchanged for the year as it continues to trade at levels last seen in January.

According to data compiled by Zack Investment Research, Cempra Inc. (NASDAQ:CEMP) is currently rated as ‘strong buy’ by one investment firm.

Melinta posting positive results on its novel treatment for mild to moderate acne vulgaris is a milestone achievement. The candidate drug not only justifies Cempra’s acquisition bid, but should strengthen the company’s pipeline of drugs.

Acne Treatment Opportunity

Acne treatments present a unique opportunity for Cempra, as it is one of the most commonly treated skin disorders and affects over 50 million Americans. Resistance to antimicrobial treatments has reportedly reached 66%.

“The results of the Phase 1 study as well as earlier testing against resistant isolates show that radezolid may have the potential to be an important treatment option for clinicians and their patients,” stated Eugene Sun, M.D., Melinta’s chief executive officer.

Melinta’s Therapeutics will carry out a 12-week randomized double-blind Phase 2 proof of concept trial to evaluate the efficacy of radezolid in approximately 48 individuals with mild to severe facial acne vulgaris. The primary endpoints of the trial will include Investigators Global Assessment score and absolute change in baseline of acne lesion.

Separately, Eurofarma Laboratories has expanded its commercialization and distribution agreement for Melintas Therapeutics’ delafloxacin drug to include 19 countries. According to the company, there is strong demand for acute skin bacteria treatment agents in Latin America.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CEMP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Endocyte, Inc. (NASDAQ:ECYT) Spikes On Prostate Cancer Deal

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT) shares gained 0.58% in Tuesday’s trading session as the stock continues to gain significant strength. Renewed investor confidence in the company follows the signing of a licensing deal for a prostate cancer candidate that represents a potential $1 billion market opportunity.

Endocyte, Inc. (NASDAQ:ECYT)

PSMA-617 License

The biopharmaceutical company stock is up by more than 300% for the month as investors continue to react to the exclusive worldwide license for PSMA-617 from ABX GmbH. The deal provides Endocyte with an advanced therapy for the treatment of prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) is currently rated as a ‘buy’ by one investment firm according to data compiled by Zack Investment Research. One firm also rates the stock as a ‘hold’.

Under the terms of the deal, Endocyte is to make a $12 million upfront payment and issue 2 million shares of its common stock. ABX is also entitled to warrants for the purchase of up to 4 million additional shares. The company could also earn up to $160 million in milestone payments and tiered royalties.

“This transaction is transformational to Endocyte, accelerating our path to commercialization. 177Lu-PSMA-617 has the potential to be the first-in-class RLT to address both bone and soft tissue disease, and it is profoundly important to the many patients suffering from mCRPC,” said Mike Sherman, President, and CEO of Endocyte.

The candidate drug is a radioligand therapeutic, designed to target the prostate-specific membrane antigen that is present in about 80% of patients suffering from metastatic castration-resistant prostate cancer. Endocyte plans to initiate a Phase 3 trial of the drug in the first half of next year with completion slated for 2020.

Endocyte Restructuring

The acquisition of worldwide rights follows the company’s June announcement that the company was focused on more valuable opportunities. A shift of focus into promising programs such as CAR T-cell SMDC adaptor platform has already come into play.

Endocyte, Inc. (NASDAQ:ECYT) is also working on EC1169 for the treatment of metastatic castration-resistant prostate cancer. It has also stopped enrollment in EC1456 trial after the program failed to achieve significant clinical activity necessary for continued advancements.

“Endocyte remains strongly committed to careful expense management and maintaining a strong balance sheet. With the exception of a very targeted effort to generate proof-of-concept data for our CAR T-cell program, we will focus our resources on the development of 177Lu-PSMA-617,” said Mr. Sherman.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ECYT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Repros Therapeutics Inc. (NASDAQ:RPRX)

Can Up Move Continue for Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX)

Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) gained 64.8% on huge volume in Friday’s trading session to end the week at $0.53 a share. However, the biopharmaceutical company continues to trade in a strong downtrend after coming under pressure earlier this year.

Repros Therapeutics Inc. (NASDAQ:RPRX) is down by more than 50% for the year as investor confidence on the stock continues to drop. Failure of the company to turn in a profit from in recent years has been the focal point of concern for investors.

Repros Therapeutics Inc. (NASDAQ:RPRX)

Financial Results Concern

For the three months ended June 30, 2017, Repros Therapeutics Inc. (NASDAQ:RPRX) posted a net loss of (-$2.2) million or (-$0.08) a share, compared to a net loss of (-$4.3) million reported last year. The company attributes the decrease to lower clinical development expenses relating to Proellex and enclomiphene.

Net Loss for the first six months of the year totaled $8.1 million compared to $9.1 million for the corresponding period last year. Total revenue and income decreased to $7,000 for the three months ended June 30, 2017, compared to $15,000 reported last year. The decrease was primarily due to lower cash balance as compared to the corresponding period last year.

General and Administrative expenditure dropped 14% in the second quarter to $906,000 due to a decrease in non-cash stock-based compensation. However, the expenditure was up by 121% for the first six months of the year to $4.7 million, mainly because of a $2.8 million charge relating to the departure of a former executive.

Repros Therapeutics Inc. (NASDAQ:RPRX) had cash and cash equivalents of $3.8 million as of June 30, 2017, compared to $8.7 million as of December 31, 2017. The decline was primarily due to increased expenditure on clinical development programs as well as administrative costs. No funds were used for investing purposes in the first half of the year.

Investors are closely awaiting the outcome of the third quarter financial results. Depending on its outcome the stock could trade in either way as it will highlight the company’ long-term prospects heading into the year-end.

Class Action Lawsuit

Separately, Repros Therapeutics Inc. (NASDAQ:RPRX) is facing a wave of class action lawsuits over claims its officers and directors engaged in securities fraud and other unlawful business practices. The claims stem from a decision by the U.S. Food and Drug Administration to place the company’s Proellex program on clinical hold pending the review of all existing liver function safety data.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Tenax Therapeutics Inc. (NASDAQ:TENX)

Is Tenax Therapeutics Inc. (NASDAQ:TENX) Sell-Off Over?

Tenax Therapeutics Inc. (NASDAQ:TENX)

Shares of Tenax Therapeutics Inc. (NASDAQ:TENX) gained 34.16% in Friday’s trading session, to end the week at $0.5098 a share.  The specialty pharmaceutical company has come under pressure this year as investors continue to question its long-term growth prospects.

TENX Stock Performance

TENX is down by more than 70% for the year as the pharmaceutical company failed to issue updates detailing developments on ongoing clinical programs.

Tenax Therapeutics Inc. (NASDAQ:TENX)

In July, Tenax Therapeutics Inc. (NASDAQ:TENX) held discussions with the U.S. Food and Drug Administration (FDA) regarding the regulatory pathway for Levosimendan. The company is investigating the candidate drug as a treatment option for patients undergoing coronary artery bypass grafting (CABG), to reduce the risk of low cardiac output syndrome. Levosimendan is also in trials for the treatment of patients with acute decompensated heart failure.

Positive Levosimendan Clinical Trials

The FDA meeting concentrated on additional analysis of Levosimendan surrounding 66% of the patients in the LEVO-CTS trial who underwent CABG alone. Initial clinical trial results indicate that patients who participated in the trial benefited from a highly significant 73% relative risk reduction in all-cause mortality.

“We are encouraged to find the data generated from the LEVO-CTS supports our continued belief that Levosimendan is an effective and safe inotrope to increase cardiac output in CABG only patients at risk for developing perioperative low cardiac output syndrome,” said CEO Michael Jebsen.

Tenax Therapeutics Inc. (NASDAQ:TENX) is currently awaiting a decision from the FDA on whether Levosimendan’s New Drug Application for the treatment of coronary bypass surgery can be filed. The agency has requested for additional information from published cross-study analyses to aid in its final decision.

Tenax Therapeutics is reviewing a number of strategic alternatives with the assistance of Ladenburg Thalmann & Co. Some of the strategies under review include a merger or a strategic investment into the company. The company is also reportedly open to license agreements as well as the acquisition of assets.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TENX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aptevo Therapeutics Inc. (NASDAQ:APVO) Expands ADAPTIR Platform

Aptevo Therapeutics Inc. (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO) traded higher after announcing the expansion of its protein therapeutic platform ADAPTIR, into new mechanisms of action including T-Cell engagers targeting CD3. In a presentation, at the World Bispecific summit, the company highlighted new improvements that it says have led to new ADAPTIR candidates.

ADAPTIR Platform Expansion

According to Aptevo Therapeutics Inc. (NASDAQ:APVO)’s Principal Scientist, Dr. Peter Pavlik, expansion of the ADAPTIR platform highlights its flexibility and versatility in generating multiple Bispecific candidates. The attributes have allowed the company to come up with T-cell engager APVO436 which targets CD123 known to cause hematological malignancies.

“Our next generation candidates, like APVO436, are designed to be delivered by intravenous dosing. With two ADAPTIR candidates currently in clinical development and a broad portfolio of Bispecific advancing in preclinical development, Aptevo has a rich pipeline of assets in the emerging field of targeted antibody therapeutics,” said Dr. Pavlik.

APVO Stock Performance

Aptevo Therapeutics Inc. (NASDAQ:APVO) bounced back after plummeting to multi-year lows of $1.15 a share continues. Earlier in the year, the stock spiked to $3.85. However, the stock is still down for the year, after retreating to end Thursday’s trading session at $2.73 a share.

Aptevo Therapeutics Inc. (NASDAQ:APVO)

Renewed investors interest follows achievements on the development of the ADAPTIR platform, which is key to the development of the company’s pipeline of drugs. The clinical stage biopharmaceutical company is currently working on APVO414 for the treatment of metastatic castration-resistant prostate cancer, as well as Otlertuzumab for the treatment of chronic lymphocytic leukemia.

Credit Facility Agreement

Separately, Aptevo Therapeutics Inc. (NASDAQ:APVO) has amended the terms of its credit agreement with Midcap Financial Trust. The amendment allows the company to keep a $20 million funding tranche. The two companies have also agreed to eliminate the option of the second tranche of $15 million.

“We are pleased to continue our relationship with MidCap Financial. They are a knowledgeable partner who understands the life sciences sector and we appreciate their continued interest in and commitment to our business,” said Jeff Lamothe, Chief Financial Officer.

Amendment of the credit facility follows the sale of three hyperimmune products by Aptevo Therapeutics Inc. (NASDAQ:APVO) to Saol Therapeutics for $74.5 million. The three products acquired include WinRho SDF for the treatment of autoimmune platelet disorder, HepaGam B for the prevention of Hepatitis B following liver transplantation and VARIZIG for treatment following varicella Zoster virus exposure.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APVO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.